BRNS (Barinthus Biotherapeutics) Accounts Payable: $0.99 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BRNS Barinthus Biotherapeutics PLC BRNS
47 GF Score
Price $0.57
GF Value $1.12
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics Accounts Payable?

Barinthus Biotherapeutics BRNS -0.02% 47 Accounts Payable is $0.99 Mil as of Mar. 2026. GuruFocus rates BRNS with a GF Score™ of 47/100 and a GF Value™ of $1.12 (Possible Value Trap). The stock has 1 warning sign investors should review.

Barinthus Biotherapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was $0.99 Mil.

Barinthus Biotherapeutics's quarterly Accounts Payable declined from Sep. 2025 ($0.70 Mil) to Dec. 2025 ($0.35 Mil) but then increased from Dec. 2025 ($0.35 Mil) to Mar. 2026 ($0.99 Mil).

Barinthus Biotherapeutics's annual Accounts Payable increased from Dec. 2023 ($1.60 Mil) to Dec. 2024 ($2.47 Mil) but then declined from Dec. 2024 ($2.47 Mil) to Dec. 2025 ($0.35 Mil).

Barinthus Biotherapeutics Accounts Payable Related Terms

Barinthus Biotherapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Barinthus Biotherapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics Accounts Payable Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 2.42 3.75 1.60 2.47 0.35

Barinthus Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.36 1.80 0.70 0.35 0.99
BRNS
47GF Score
Barinthus Biotherapeutics PLC BRNS
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Barinthus Biotherapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.99 Mil mean?
Barinthus Biotherapeutics (BRNS) has a Accounts Payable of $0.99 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Barinthus Biotherapeutics and its competitors.
Is Barinthus Biotherapeutics' Accounts Payable too high?
Barinthus Biotherapeutics' current Accounts Payable is $0.99 Mil. Overall, Barinthus Biotherapeutics has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Accounts Payable compare to CRVO and ALGS?
Barinthus Biotherapeutics' Accounts Payable of $0.99 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current Accounts Payable is $0.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Barinthus Biotherapeutics (BRNS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.12, compared to a current price of $0.57 — trading 49.1% below its estimated fair value. The current Accounts Payable is $0.99 Mil. Barinthus Biotherapeutics' overall GF Score™ is 47/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Barinthus Biotherapeutics (BRNS), the current Accounts Payable is $0.99 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (BRNS) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of $0.57 is trading 49.1% below its estimated GF Value™ of $1.12. GuruFocus considers Barinthus Biotherapeutics to be Possible Value Trap.

Key valuation signals for BRNS:

  • Accounts Payable: $0.99 Mil
  • GF Value™: $1.12 vs. price of $0.57 (49.1% below fair value)
  • GF Score™: 47/100 with 1 warning sign

No single metric tells the full story. See the BRNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
47GF Score

Get the complete analysis for BRNS

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.57
Price
$1.12
GF Value